NEW YORK, NY--(Marketwire -07\/24\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on StemCells, Inc. (STEM) and Keryx Biopharmaceuticals (KERX). <\/p>\n
Access to the full company reports can be found at: <\/p>\n
http:\/\/www.ParagonReport.com\/STEM<\/a> http:\/\/www.ParagonReport.com\/KERX<\/a> <\/p>\n Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is \"so high that prices are more easily accepted by the regulators.\" <\/p>\n Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http:\/\/www.ParagonReport.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n StemCells is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The company recently announced preclinical data demonstrating that its proprietary human neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease. Shares of the company have soared nearly 90 percent this year. <\/p>\n Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Shares of the company have rebounded nearly 50 percent over the last three months. <\/p>\n The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http:\/\/www.paragonreport.com\/disclaimer<\/a> <\/p>\n<\/p>\n Continue reading here: NEW YORK, NY--(Marketwire -07\/24\/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. Continue reading
\nStemCells and Keryx Biopharmaceuticals Showing Strong Gains as Biotechnology Industry Soars in 2012<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"